Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tekturna's future looks dim as Novartis cuts 1,960 jobs

This article was originally published in Scrip

Executive Summary

The future of Novartis's antihypertensive Tekturna/Rasilez (aliskiren) is looking increasingly bleak after the company announced today that it would accelerate planned sales force job cuts because of the recent failure of a major trial of the product. The Swiss firm is to cut its US field force by 1,630 positions and reduce staff at headquarters in New Jersey by 330 positions.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015898

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel